10 results about "Heparan sulfate" patented technology

Disclosed is a method of treating liver ischemia reperfusion (I / R) injury in a subject. In some aspects, the method comprises providing a subject suffering from liver I / R injury or at risk of suffering liver I / R injury; and administering to the subject one or more heparan sulfate (HS) compounds. In some aspects, the one or more HS compounds comprises about 5 to about 18 saccharide units, optionally about 12 to about 18 saccharide units. In some aspects, the one or more HS compounds comprises about 12 saccharide units.

The invention relates to the technical field of artificial design of enzymes, in particular to an artificial intelligence design and expression system construction method and system for lysosomal membrane protein type N-acetyltransferase with 11 transmembrane regions, and the method comprises the following steps: collecting reaction rate information of an enzyme and a substrate, associating a structure model with rate parameters, and comparing three-dimensional difference of residues, according to the method, by collecting the reaction rate correlation structure conformation, dynamic recognition of the key conformation state is achieved, the accuracy of three-dimensional space difference analysis is improved, host expression optimization factors are fused in the construction process, and the construction efficiency is improved. According to the method, the expression efficiency is improved, conformation function screening and structural stability parallel evaluation are carried out, the screening accuracy of efficient catalysis and stable expression is enhanced, three links of recognition, screening and construction are broken through, the target enzyme obtaining efficiency and expression quality are improved, and enzyme engineering is promoted to be developed towards high-throughput systematization.

This invention discloses a recombinant 2-O-sulfonyltransferase mutant and its preparation method, belonging to the field of biotechnology. The recombinant enzyme sequence is formed by fusing a truncated (E28~N356) mutant of hamster-derived 2-O-sulfonyltransferase (L119V-R188E-A240I) with an N-terminal maltose-binding protein (MBP) tag. The recombinant 2-O-sulfonyltransferase mutant exhibits higher activity, 1.9 times that of the recombinant wild type, and greater stability, retaining 86.6% of its activity after 5 days at room temperature. Furthermore, the soluble expression level of this recombinant mutant 2-O-sulfonyltransferase is increased by 5 times. This mutant, as a novel biocatalyst with high efficiency, stability, and controllable production costs, has significant application value and broad industrialization prospects in the industrial enzymatic synthesis of glycosaminoglycans such as heparin and heparan sulfate.

The present invention relates to a pharmaceutical composition for preventing or treating Sanfilippo syndrome type A (MPS IIIA) comprising heparan N-sulfatase (HNS), and more particularly, to an optimal dose and period of administration of heparan N-sulfatase, which can effectively reduce the accumulation of heparan sulfate (HS) while improving the cognition of patients. According to the present invention, it can be used as enzyme replacement therapy (ERT) for treating Sanfilippo syndrome type A.

Enhanced recombinant adeno-associated viruses (rAAVs) (e.g., rAAV2, rAAVrh8R, etc.) are provided herein for improved gene therapy of eye or central nervous system (CNS) disorders, wherein the rAAV comprises one or more amino acid substitutions that interact with the heparan sulfate proteoglycan. The invention provides methods for enhancing retinal cell transduction and methods for treating eye diseases with enhanced compositions of rAAV particles. Furthermore, enhanced recombinant adeno-associated viruses (rAAVs) (e.g., rAAV2, rAAVrh8R, etc.) are provided herein for improved gene therapy of CNS disorders. The invention provides methods for delivering the rAAV to the CNS, methods for treating CNS disorders with enhanced compositions of rAAV particles, and kits for delivering the rAAV to the CNS and / or treating a CNS disorder.

Methods and compositions for diagnosing, preventing or treating a viral infection in a subject comprising administering to a subject in need thereof an effective amount of a glycosidase or a sulfatase to degrade a glycan, such as heparan sulfate, to inhibit viral infection, such as COVID-19. Methods for identifying a glycosidase, a sulfatase, or a microbe associated with increased susceptibility to viral infection in a subject.

The present invention relates to heparan sulfate sugar mimetic compounds as heparan sulfate mimetics, and the use of these compounds as medicaments, cosmeceuticals and as molecular probes. The invention also relates to intermediate compounds useful in the preparation of various sugar mimetic compounds. The invention is particularly suitable for treating or preventing diseases such as cancer, inflammation, diabetic nephropathy, neurodegenerative diseases, for bone healing or wound healing, for cosmeceutical use, and as molecular probes comprising imaging agents.

The application provides application of lactoferrin and a composition thereof in promoting intestinal development. The lactoferrin of the application can up-regulate the transcription level of a phospholipid globulin polysaccharide coding gene gpc1, a hyaluronic acid synthase 1 coding gene has1, a hyaluronic acid synthase 2 coding gene has2, a hyaluronic acid synthase 3 coding gene has3, an exosin glycosyltransferase 1 coding gene ext1 and an exosin glycosyltransferase 2 coding gene ext2, thereby promoting development of a protein skeleton of a glycocalyx layer, synthesis of hyaluronic acid, synthesis of heparan sulfate, further promoting development of the glycocalyx layer, and achieving the effects of perfecting an intestinal barrier, regulating intestinal flora and improving intestinal health.

The application provides application of casein phosphopeptide in promoting development of a sugar layer of an intestinal tract and preparation of related products. The casein phosphopeptide can up-regulate transcription levels of a coding gene gpc1 of phospholipid globulin polysaccharide, a coding gene has1 of hyaluronic acid synthetase 1, a coding gene has2 of hyaluronic acid synthetase 2, a coding gene has3 of hyaluronic acid synthetase 3, a coding gene ext1 of exosin glycosyltransferase 1 and a coding gene ext2 of exosin glycosyltransferase 2, thereby promoting development of a protein skeleton of the sugar layer, synthesis of hyaluronic acid and synthesis of heparan sulfate, further promoting development of the sugar layer, and achieving the effects of perfecting an intestinal tract barrier, regulating intestinal flora and improving intestinal health.

Disclosed herein are cellular derived heparin and heparan sulfate compositions, methods of making and using, and cell lines for making and using.